Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login



Triple combination antihypertensive pill effective for blood pressure control

Research into the effectiveness of a triple combination antihypertensive pill has shown promising results that could mean improved access to care in low-income countries, and better blood pressure control in more affluent countries

Doctor measuring a patient's blood pressure


A triple-combination antihypertensive pill has shown promising results that could mean improved access to care and better blood pressure control

A fixed-dose triple combination antihypertensive pill is more effective at controlling blood pressure than usual care, the results of a randomised trial in Sri Lanka show[1].

The study involved 700 patients with mild-to-moderate hypertension who required escalation (if they were already receiving monotherapy) or initiation of antihypertensive treatment. They were randomly assigned to a once-daily fixed-dose pill containing telmisartan 20mg, amlodipine 2.5mg and chlorthalidone 12.5mg, or usual care.

At six months, 70% of those assigned to the combination pill had achieved the target blood pressure, compared with 55% among those assigned to usual care. The mean blood pressure was 125/76mmHg and 134/81mmHg in each group, respectively.

The researchers explained that hypertension is undertreated in low- and middle-income countries, which is partly a result of affordability and accessibility. A fixed-dose pill could help address these issues.

The findings also lend support to the use of combination therapy in high-income countries, like the UK, which also struggle to achieve blood pressure targets.

“Use of such medication as initial therapy or to replace monotherapy may be an effective way to improve blood pressure control,” the authors concluded in the Journal of the American Medical Association.

Citation: Clinical Pharmacist DOI: 10.1211/CP.2018.20205427

Readers' comments (2)

  • So why have the big pharmaceutical Companies not invested in bringing such licensed product on the market?
    Is it because of cost to get a licensed product launched or other issues?

    Unsuitable or offensive? Report this comment

  • Why pharmaceutical Companies, not Investment in bringing such licensed product on the market?

    Unsuitable or offensive? Report this comment

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.